Ibrutinib Facilitates the Sensitivity of Colorectal Cancer Cells to Ferroptosis through BTK/NRF2 Pathway

Ibrutinib sensitized colorectal cancer (CRC) to ferroptosis inducers, suggested by reduced CRC cell viability, proliferation, and decreased antioxidant protein levels in CRC cells after combination treatment of Ibrutinib and RSL3 or Ibrutinib and Erastin both in vivo and in vitro.